Free Trial
NYSE:KVUE

Kenvue (KVUE) Stock Price, News & Analysis

$21.70
+0.14 (+0.65%)
(As of 08/21/2024 ET)
Today's Range
$21.57
$21.85
50-Day Range
$17.69
$21.70
52-Week Range
$17.67
$24.10
Volume
8.45 million shs
Average Volume
18.98 million shs
Market Capitalization
$41.54 billion
P/E Ratio
27.81
Dividend Yield
3.78%
Price Target
$22.64

Kenvue MarketRank™ Stock Analysis

Analyst Rating
Hold
2.31 Rating Score
Upside/​Downside
4.3% Upside
$22.64 Price Target
Short Interest
Healthy
1.58% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
1.35mentions of Kenvue in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
10.62%
From $1.13 to $1.25 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.61 out of 5 stars

Consumer Staples Sector

61st out of 132 stocks

Toilet Preparations Industry

6th out of 13 stocks

KVUE stock logo

About Kenvue Stock (NYSE:KVUE)

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

KVUE Stock Price History

KVUE Stock News Headlines

PepsiCo logo on building
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon (KVUE)
These three stocks have a long history of increasing their dividends and are likely to benefit from sector rotation on expectations of lower interest rates
Tylenol ADHD lawsuits cannot go forward, judge rules
This technology could swing the election
Hidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard - in the heart of Appalachia.
This technology could swing the election
Hidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard - in the heart of Appalachia.
7 Stable Dividend Stocks to Scoop Up on Discount
Kenvue Inc. (NYSE:KVUE) Raises Dividend to $0.21 Per Share
Kenvue: Promising Steps Toward Long-Term Success
Kenvue Inc. (KVUE) Q2 2024 Earnings Call Transcript
Kenvue Goes Boom - Now What?
See More Headlines
Receive KVUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kenvue and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2024
Ex-Dividend for 8/28 Dividend
8/14/2024
Today
8/21/2024
Dividend Payable
8/28/2024
Next Earnings (Estimated)
10/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Toilet preparations
Sub-Industry
Consumer Goods
Fax
N/A
Employees
22,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.64
High Stock Price Target
$28.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+4.3%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$1.66 billion
Pretax Margin
12.97%

Debt

Sales & Book Value

Annual Sales
$15.48 billion
Cash Flow
$1.83 per share
Book Value
$5.85 per share

Miscellaneous

Outstanding Shares
1,914,815,000
Free Float
1,911,560,000
Market Cap
$41.54 billion
Optionable
Optionable
Beta
1.38
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Thibaut Mongon (Age 53)
    CEO & Director
    Comp: $4.79M
  • Mr. Paul Ruh (Age 56)
    Chief Financial Officer
    Comp: $2.33M
  • Ms. Meredith Stevens (Age 61)
    Chief Operations Officer
    Comp: $1.84M
  • Mr. Carlton Lawson (Age 55)
    Group President of EMEA & Latin America
    Comp: $2.28M
  • Ms. Ellie Bing Xie (Age 54)
    Group President of Asia Pacific
    Comp: $2.94M
  • Ms. Heather R. Howlett (Age 46)
    Chief Accounting Officer
  • Mr. Bernardo Tavares (Age 56)
    Chief Data & Technology Officer
  • Dr. Caroline Tillett (Age 52)
    Chief Scientific Officer
  • Ms. Tina Romani
    Head of Investor Relations
  • Mr. Matthew Orlando (Age 47)
    General Counsel

Should I Buy Kenvue Stock? KVUE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Kenvue Inc.:

  • Kenvue's current stock price is $18.75, which may present a buying opportunity for investors looking to enter at a lower price point.
  • The company recently increased its quarterly dividend from $0.20 to $0.205, indicating a positive outlook on future earnings and cash flow.
  • Kenvue's return on equity stands at 21.06%, showcasing the company's ability to generate profit from shareholders' equity.
  • The company operates in three segments: Self Care, Skin Health and Beauty, and Essential Health, providing diversification in its revenue streams.
  • Despite revenue being down 24.9% year-over-year, Kenvue beat earnings estimates, demonstrating strong operational efficiency.

Cons

Investors should be bearish about investing in Kenvue Inc. for these reasons:

  • Analysts have given the company an average rating of "Hold," indicating uncertainty in the stock's future performance.
  • The company's revenue decline of 24.9% year-over-year may raise concerns about its ability to drive top-line growth in the future.
  • Kenvue's dividend payout ratio is currently 102.56%, which suggests that the company is paying out more in dividends than it is earning, potentially unsustainable in the long run.
  • With a beta of 1.41, Kenvue's stock is more volatile compared to the market average, posing higher risk for investors.
  • Despite beating earnings estimates, Kenvue's revenue of $2.89 billion fell short of analyst expectations of $3.79 billion, indicating potential challenges in revenue generation.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 13, 2024. Please send any questions or comments about these Kenvue pros and cons to contact@marketbeat.com.

KVUE Stock Analysis - Frequently Asked Questions

How have KVUE shares performed this year?

Kenvue's stock was trading at $21.53 at the start of the year. Since then, KVUE shares have increased by 0.8% and is now trading at $21.6950.
View the best growth stocks for 2024 here
.

How were Kenvue's earnings last quarter?

Kenvue Inc. (NYSE:KVUE) announced its earnings results on Tuesday, August, 6th. The company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.04. Kenvue's revenue for the quarter was down .3% on a year-over-year basis.

When did Kenvue IPO?

Kenvue (KVUE) raised $3.3 billion in an initial public offering on Thursday, May 4th 2023. The company issued 151,200,000 shares at $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, Citigroup, Deutsche Bank Securities, BNP PARIBAS, HSBC, RBC Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

Who are Kenvue's major shareholders?

Kenvue's top institutional investors include Massachusetts Financial Services Co. MA (4.17%), Bank of New York Mellon Corp (2.27%), American Century Companies Inc. (1.43%) and Van ECK Associates Corp (1.07%).
View institutional ownership trends
.

How do I buy shares of Kenvue?

Shares of KVUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:KVUE) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners